Table 1. Incidence and predictors of pregnancy at enrollment (n = 40).
| Variables | Pregnant, n = 8 (%) | Non-pregnant, n = 32 (%) |
|---|---|---|
| FEMALE PARTNER FACTORS | ||
| Age–Median (Q1 –Q3) | 29 (22.0–32.0) | 27 (23.5–31.0) |
| Work outside the home | 3 (43) | 18 (60) |
| Level of Education | ||
| Some Primary | 0 (0) | 17 (71) |
| Some secondary | 3 (43) | 2 (8) |
| Some post-secondary | 4 (57) | 5 (21) |
| AIDS-Defining Illness | ||
| Yes | 0 (0) | 4 (12) |
| No | 7 (100) | 28 (88) |
| WHO stage (initiation of care) | ||
| 1 | 5 (62) | 19 (59) |
| 2 | 3 (38) | 8 (25) |
| 3 | 0 (0) | 3 (9) |
| 4 | 0 (0) | 2 (6) |
| Current ARV use | 4 (50) | 21 (66) |
| Prior ARV usea | 4 (50) | 21 (66) |
| History of STI (gonorrhea, chlamydia, trichomonas, HSV) | 2 (25) | 12 (38) |
| History of PIDa | ||
| Yes | 0 (0) | 0 (0) |
| No | 8 (100) | 32 (100) |
| BMI at enrollment–Median (Q1- Q3) | 24.1 (22.2–26.8) | 21.9 (19.1–24.6) |
| CD4 count/mm3 at enrollment median (Q1- Q3) | 479 (447.5–739.5) | 480.5 (367–574.5) |
| Number of prior pregnanciesa | ||
| 0 | 1 (12) | 5 (16) |
| 1 | 2 (25) | 9 (28) |
| 2 | 3 (38) | 12 (38) |
| 3+ | 2 (25) | 6 (19) |
| Number of living childrena | ||
| 0 | 3 (38) | 10 (31) |
| 1 | 3 (38) | 10 (31) |
| 2 | 1 (12) | 8 (25) |
| 3+ | 1 (12) | 4 (12) |
| Years since HIV diagnosis median (Q1 –Q3) | 4.3 (1.3–7.4) | 2.2 (1.0–5.5) |
| Current method of contraception | ||
| None | 0 (0) | 11 (36) |
| Oral tablets | 0 (0) | 3 (10) |
| Depo Provera® (DMPA) | 0 (0) | 3 (10) |
| Other/traditional family planning | 8 (100) | 13 (43) |
| Condom use at enrollment | ||
| 100% | 8 (100) | 21 (66) |
| 50–99% | 0 (0) | 8 (25) |
| <50% | 0 (0) | 3 (9) |
| MALE PARTNER FACTORS | ||
| Age–Median (Q1-Q3) | 33.5 (25.5–39.0) | 33.5 (28.5–35.0) |
| History of STIa | 2 (25) | 10 (32) |
| Treated for STIa | 2 (25) | 7 (22) |
| Circumciseda | 2 (25) | 17 (53) |
| Number of living childrena | ||
| 0 | 3 (38) | 10 (31) |
| 1 | 3 (38) | 8 (25) |
| 2 | 1 (12) | 8 (25) |
| 3+ | 1 (12) | 6 (19) |
| Condom use at enrollmenta | ||
| 100% | 6 (75) | 23 (72) |
| 50–99% | 2 (25) | 7 (22) |
| <50% | 0 (0) | 2 (6) |
ARV–antiretroviral therapy; WHO–World Health Organization; STI–sexually transmitted infection;
DMPA–Depot medroxyprogesterone acetate; HSV–herpes simplex virus; PID–pelvic inflammatory disease
aIndicates data was self-reported by patient